180 related articles for article (PubMed ID: 38573129)
1. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.
Dohna M; Voskrebenzev A; Klimeš F; Kaireit TF; Glandorf J; Pallenberg ST; Ringshausen FC; Hansen G; Renz DM; Wacker F; Dittrich AM; Vogel-Claussen J
Radiol Cardiothorac Imaging; 2024 Apr; 6(2):e230104. PubMed ID: 38573129
[TBL] [Abstract][Full Text] [Related]
2. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
[TBL] [Abstract][Full Text] [Related]
3. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
[No Abstract] [Full Text] [Related]
4. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study.
Blardone C; Gambazza S; Mariani A; Galgani R; Brivio A; Nobili RM; Rizza C; Tutino AL; Gramegna A; Daccò V; Contarini M; Blasi F; Laquintana D
Ther Adv Respir Dis; 2024; 18():17534666241235054. PubMed ID: 38554035
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
7. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
8. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
[No Abstract] [Full Text] [Related]
9. Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report.
Bec R; Reynaud-Gaubert M; Arnaud F; Naud R; Dufeu N; Di Bisceglie M; Coiffard B; Gaubert JY; Bermudez J; Habert P
Eur J Radiol; 2022 Sep; 154():110421. PubMed ID: 35772339
[TBL] [Abstract][Full Text] [Related]
10. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
[TBL] [Abstract][Full Text] [Related]
11. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
[TBL] [Abstract][Full Text] [Related]
12. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.
Wiesel V; Aviram M; Mei-Zahav M; Dotan M; Prais D; Cohen-Cymberknoh M; Gur M; Bar-Yoseph R; Livnat G; Goldbart A; Hazan G; Hazan I; Golan-Tripto I
J Cyst Fibros; 2024 Jan; 23(1):41-49. PubMed ID: 37173154
[TBL] [Abstract][Full Text] [Related]
13. Impact of elexacaftor/tezacaftor/ivacaftor on respiratory colonization in an adult cystic fibrosis clinic.
Szabo MM; Foushee SE; McPheeters CM; O'Hagan AR; Ramirez AM; O'Reilly EA
Am J Med Sci; 2024 May; 367(5):337-342. PubMed ID: 38336262
[TBL] [Abstract][Full Text] [Related]
14. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
[TBL] [Abstract][Full Text] [Related]
15. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
[TBL] [Abstract][Full Text] [Related]
17. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
[TBL] [Abstract][Full Text] [Related]
18. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
[No Abstract] [Full Text] [Related]
19. Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis.
Dittrich AM; Sieber S; Naehrlich L; Burkhart M; Hafkemeyer S; Tümmler B;
Int J Infect Dis; 2024 Feb; 139():124-131. PubMed ID: 38036261
[TBL] [Abstract][Full Text] [Related]
20. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]